Literature DB >> 1651735

Tests of opioid deficiency hypotheses of alcoholism.

L D Reid1, J D Delconte, M L Nichols, E J Bilsky, C L Hubbell.   

Abstract

Eighty-three male rats were maintained on a daily regimen involving 22 h of deprivation of fluids followed by 2 h of access to water and a sweetened alcoholic beverage (12% ethanol, 5% sucrose). After about 3 weeks of such a regimen, rats eventually take considerable amounts of ethanol daily. In the present study, a series of injections of opioids was given subsequent to establishing stable daily intakes of ethanol. Specifically, before a day's opportunity to take fluids, some rats were given a small dose of morphine (2.0 mg/kg), while others were given a dose of naloxone (4.0 mg/kg). When morphine was given 0.5 h before the opportunity to drink, intake of ethanol was increased. However, when morphine was given 4.0 h before the opportunity, intake of ethanol was decreased. Nearly opposite effects were observed when naloxone was given. Other experiments tested the effects of giving morphine 4.0 h before the opportunity to drink plus the effects of a small dose of naloxone or plus the effects of a small dose of morphine. Morphine given 4.0 h before potentiated the effects of a small dose of naloxone and attenuated the effects of another dose of morphine. The effects of morphine were also shown to be similar among rats taking a solution of ethanol and water rather than a sweetened solution. These data provide support for the idea that surfeits, not deficits, in opioidergic activity increase propensity to take alcoholic beverages.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651735     DOI: 10.1016/0741-8329(91)90305-g

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  10 in total

Review 1.  The opioidergic-alcohol link : implications for treatment.

Authors:  Vania Modesto-Lowe; Eleanor M Fritz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Authors:  Lauren E Hood; Jonna M Leyrer-Jackson; M Foster Olive
Journal:  Expert Opin Pharmacother       Date:  2020-02-27       Impact factor: 3.889

3.  Alleviating waiting impulsivity and perseverative responding by μ-opioid receptor antagonism in two inbred mouse strains.

Authors:  Sandra Sanchez-Roige; Tamzin L Ripley; David N Stephens
Journal:  Psychopharmacology (Berl)       Date:  2014-11-08       Impact factor: 4.530

4.  Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse.

Authors:  Marie N S Gendy; Clement Zai; Bernard Le Foll; James L Kennedy
Journal:  Can J Addict       Date:  2019-12

5.  Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists.

Authors:  C Fahlke; E Hård; C J Eriksson; J A Engel; S Hansen
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  Morphine induced changes in ethanol-and water-intake are attenuated by the 5-HT3/4 antagonist tropisetron (ICS 205-930).

Authors:  C W Hodge; J S Niehus; H H Samson
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

Review 7.  Genetics of alcoholism: role of the endogenous opioid system.

Authors:  C Gianoulakis; J P de Waele
Journal:  Metab Brain Dis       Date:  1994-06       Impact factor: 3.584

Review 8.  Opioid antagonists in the treatment of alcohol dependence.

Authors:  G O'Leary; J Borrow; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

9.  Neuropeptides as mediators of the early-life impact on the brain; implications for alcohol use disorders.

Authors:  Ingrid Nylander; Erika Roman
Journal:  Front Mol Neurosci       Date:  2012-07-05       Impact factor: 5.639

10.  Capsaicin Reduces Ethanol Consumption in C57BL/6 but not DBA/2 Mice.

Authors:  Sung Young Huh; Sung-Gon Kim; Hyeon-Kyeong Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.